 Fiona Zwald
Concepts (101)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 13 | 2024 | 855 | 2.690 |
Why?
| | Organ Transplantation | 9 | 2024 | 250 | 2.530 |
Why?
| | Melanoma | 5 | 2024 | 760 | 1.550 |
Why?
| | Carcinoma, Squamous Cell | 7 | 2021 | 683 | 1.190 |
Why?
| | Transplant Recipients | 5 | 2025 | 184 | 1.180 |
Why?
| | Mohs Surgery | 2 | 2015 | 27 | 0.860 |
Why?
| | Transplants | 1 | 2020 | 36 | 0.660 |
Why?
| | Neoplasms, Second Primary | 1 | 2021 | 118 | 0.640 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2024 | 1079 | 0.490 |
Why?
| | Carcinoma, Merkel Cell | 1 | 2016 | 17 | 0.490 |
Why?
| | Curettage | 1 | 2013 | 8 | 0.420 |
Why?
| | Dermatology | 1 | 2015 | 127 | 0.410 |
Why?
| | Electrocoagulation | 1 | 2013 | 40 | 0.410 |
Why?
| | Career Choice | 1 | 2015 | 219 | 0.410 |
Why?
| | Dermatofibrosarcoma | 1 | 2012 | 9 | 0.390 |
Why?
| | Neoplasms | 3 | 2025 | 2671 | 0.390 |
Why?
| | Carcinoma, Basal Cell | 1 | 2013 | 75 | 0.380 |
Why?
| | Academic Medical Centers | 1 | 2015 | 512 | 0.380 |
Why?
| | Faculty, Medical | 1 | 2015 | 283 | 0.380 |
Why?
| | Kidney Transplantation | 2 | 2025 | 708 | 0.370 |
Why?
| | Histiocytoma, Malignant Fibrous | 1 | 2011 | 6 | 0.370 |
Why?
| | Immunosuppressive Agents | 4 | 2025 | 890 | 0.370 |
Why?
| | Histiocytoma, Benign Fibrous | 1 | 2011 | 8 | 0.370 |
Why?
| | Antifungal Agents | 1 | 2012 | 136 | 0.360 |
Why?
| | Triazoles | 1 | 2012 | 147 | 0.350 |
Why?
| | Pyrimidines | 2 | 2017 | 470 | 0.320 |
Why?
| | Prognosis | 6 | 2025 | 4030 | 0.310 |
Why?
| | Lung Transplantation | 1 | 2012 | 313 | 0.300 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1587 | 0.280 |
Why?
| | Incidence | 4 | 2025 | 2804 | 0.240 |
Why?
| | Heart Transplantation | 1 | 2011 | 754 | 0.230 |
Why?
| | Abatacept | 1 | 2025 | 53 | 0.230 |
Why?
| | Risk Factors | 7 | 2025 | 10388 | 0.230 |
Why?
| | Liver Transplantation | 1 | 2011 | 871 | 0.210 |
Why?
| | Survival Rate | 2 | 2025 | 1972 | 0.190 |
Why?
| | Postoperative Complications | 2 | 2025 | 2654 | 0.190 |
Why?
| | Humans | 21 | 2025 | 137585 | 0.190 |
Why?
| | Keratosis, Actinic | 1 | 2021 | 12 | 0.180 |
Why?
| | Graft Rejection | 1 | 2025 | 624 | 0.170 |
Why?
| | Early Detection of Cancer | 1 | 2024 | 447 | 0.150 |
Why?
| | Kidney Failure, Chronic | 1 | 2025 | 570 | 0.150 |
Why?
| | Hematologic Neoplasms | 1 | 2020 | 156 | 0.150 |
Why?
| | Follow-Up Studies | 2 | 2025 | 5131 | 0.140 |
Why?
| | Chemoprevention | 1 | 2018 | 92 | 0.140 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2018 | 57 | 0.140 |
Why?
| | Middle Aged | 6 | 2025 | 33479 | 0.130 |
Why?
| | Janus Kinase Inhibitors | 1 | 2017 | 26 | 0.130 |
Why?
| | Neoplasm Staging | 2 | 2018 | 1389 | 0.130 |
Why?
| | International Agencies | 1 | 2016 | 35 | 0.120 |
Why?
| | Male | 8 | 2025 | 67762 | 0.120 |
Why?
| | Registries | 1 | 2024 | 2035 | 0.120 |
Why?
| | Professional Autonomy | 1 | 2015 | 30 | 0.120 |
Why?
| | Private Practice | 1 | 2015 | 25 | 0.120 |
Why?
| | Personnel Turnover | 1 | 2015 | 40 | 0.120 |
Why?
| | Salaries and Fringe Benefits | 1 | 2015 | 56 | 0.120 |
Why?
| | Immunocompromised Host | 2 | 2018 | 202 | 0.120 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2015 | 96 | 0.110 |
Why?
| | Workload | 1 | 2015 | 167 | 0.100 |
Why?
| | Pyrazoles | 1 | 2017 | 423 | 0.100 |
Why?
| | Research Personnel | 1 | 2015 | 173 | 0.100 |
Why?
| | Aged | 4 | 2025 | 23961 | 0.100 |
Why?
| | Cooperative Behavior | 1 | 2015 | 451 | 0.100 |
Why?
| | Data Collection | 1 | 2015 | 673 | 0.100 |
Why?
| | Voriconazole | 1 | 2012 | 20 | 0.090 |
Why?
| | Mycoses | 1 | 2012 | 79 | 0.090 |
Why?
| | Leadership | 1 | 2015 | 388 | 0.090 |
Why?
| | Female | 5 | 2025 | 73304 | 0.080 |
Why?
| | Disease Progression | 1 | 2018 | 2757 | 0.080 |
Why?
| | United States | 2 | 2025 | 14841 | 0.080 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2010 | 115 | 0.080 |
Why?
| | Combined Modality Therapy | 1 | 2011 | 1236 | 0.070 |
Why?
| | Consensus | 2 | 2020 | 683 | 0.070 |
Why?
| | Attitude of Health Personnel | 1 | 2015 | 1171 | 0.070 |
Why?
| | Young Adult | 1 | 2024 | 13209 | 0.070 |
Why?
| | Kidney Function Tests | 1 | 2025 | 160 | 0.060 |
Why?
| | Adolescent | 1 | 2024 | 21513 | 0.060 |
Why?
| | Adult | 2 | 2025 | 37929 | 0.050 |
Why?
| | Graft Survival | 1 | 2025 | 535 | 0.050 |
Why?
| | Glomerular Filtration Rate | 1 | 2025 | 746 | 0.040 |
Why?
| | Delphi Technique | 1 | 2021 | 280 | 0.040 |
Why?
| | Aged, 80 and over | 1 | 2011 | 7635 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2024 | 2031 | 0.040 |
Why?
| | Aminoquinolines | 1 | 2018 | 19 | 0.040 |
Why?
| | Capecitabine | 1 | 2018 | 45 | 0.040 |
Why?
| | Administration, Cutaneous | 1 | 2018 | 129 | 0.040 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2018 | 94 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2018 | 220 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2018 | 307 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2018 | 389 | 0.030 |
Why?
| | Lymphatic Metastasis | 1 | 2018 | 352 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2017 | 155 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2024 | 10811 | 0.030 |
Why?
| | Nitriles | 1 | 2017 | 172 | 0.030 |
Why?
| | Sirolimus | 1 | 2018 | 276 | 0.030 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2018 | 249 | 0.030 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 190 | 0.030 |
Why?
| | Lymph Nodes | 1 | 2018 | 491 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 411 | 0.030 |
Why?
| | Risk Assessment | 1 | 2024 | 3457 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2018 | 614 | 0.030 |
Why?
| | Retrospective Studies | 1 | 2025 | 15657 | 0.020 |
Why?
|
|
Zwald's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|